Multiple Myeloma

COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma Patients

Publish Date August 6, 2020

Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks versus white patients.

Patient Death Puts Trial on Hold for Universal CAR-T in Myeloma

By

Christina Bennett, MS

Publish Date July 22, 2020

The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.

Migration Inhibitory Factor May Influence Proteasome Inhibitor Sensitivity in MM

By

Vicki Moore, PhD

Publish Date July 16, 2020

MM cells expressing high levels of migration inhibitory factor may have poorer responses to proteasome inhibitors, resulting in adverse patient outcomes.

Doublet vs Triplet Bortezomib-Based Therapy for Renal Recovery in Myeloma Cast Nephropathy

By

Vicki Moore, PhD

Publish Date July 15, 2020

For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.

Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

Publish Date June 16, 2020

Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.